高危不确定局灶性肝脏病灶(CT/MRI 分类为 LR-4 或 LR-M)的超声造影表现
该研究为前瞻性国际多中心 CEUS LI-RADS 验证研究的二次分析,纳入 109 例参与者共 113 个 ≥10 mm 的 CT/MRI LR-4 或 LR-M 病灶。CEUS 使 33.6% 的病灶管理建议发生改变,其中 95% 改变正确;30.1% 的病灶经 CEUS 归为 LR-5,94% 正确;对 ≥20 mm 病灶临床影响更大,管理建议改变 40% 且 100% 准确。
要点
- CEUS 可将部分 CT/MRI LR-4 或 LR-M 病灶明确为 LR-5,30.1%(34/113)归为 LR-5 后无需活检,94%(32/34)正确。
- CEUS 使 33.6%(38/113)的病灶管理建议改变,其中 95%(36/38)改变正确。
- ≥20 mm 病灶(n=68)CEUS 管理建议改变 40%(27/68)且 100% 准确,临床影响更显著。
核心结论
- CEUS 可解决部分 CT/MRI 分类为 LR-4 和 LR-M 的高危不确定肝脏病灶,对 ≥20 mm 病灶的临床影响尤其高。
研究设计与样本
- 前瞻性国际多中心 CEUS LI-RADS 验证研究的二次分析,纳入 109 例参与者共 113 个 ≥10 mm 病灶,CEUS 在 CT/MRI 后 4 周内进行,以组织学及 CT/MRI 随访为参考标准。
关键影像表现/征象
- CEUS 将 30.1%(34/113)的 CT/MRI LR-4 或 LR-M 病灶归为 LI-RADS LR-5(明确 HCC),使活检不再必要,其中 94%(32/34)分类正确。
- CT/MRI LR-4 病灶中 7%(4/60)经 CEUS 归为 LR-M,后续活检均证实为非 HCC 恶性肿瘤。
- CEUS 使 33.6%(38/113)的病灶管理建议发生改变,其中 95%(36/38)改变正确。
临床应用与阅片要点
- 对 CT/MRI 分类为 LR-4 或 LR-M 的高危不确定肝脏病灶,CEUS 可提供额外分类信息以辅助管理决策。
- CEUS 将病灶归为 LR-5 时,94%(32/34)的分类正确,可使部分患者免于活检。
- 对 ≥20 mm 的病灶,CEUS 管理建议改变 40%(27/68)且 100% 准确,临床影响更显著。
- CT/MRI LR-4 病灶经 CEUS 归为 LR-M 时,后续活检均证实为非 HCC 恶性肿瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Indeterminate focal liver observations in patients at risk for hepatocellular carcinoma (HCC) may require invasive biopsy or follow-up, which could lead to delays in definitive categorization and to postponement of treatment. Purpose To examine clinical effect of contrast-enhanced US (CEUS) in participants with high-risk indeterminate liver observations categorized as Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) or LI-RADS category LR-M (probably or definitely malignant but not HCC specific) at CT or MRI. Materials and Methods This was a secondary analysis of a prospective international multicenter validation study for CEUS LI-RADS (January 2018 to August 2021). CEUS was performed within 4 weeks of CT or MRI. Tissue histologic and CT or MRI follow-up data were used as reference standards. Clinical effect of CEUS for HCC was evaluated in observations 10 mm or larger categorized as CT/MRI LR-4 and LR-M. Results Included were 109 participants (mean age, 64.3 years ± 8.3 [SD]; 68.8% [75 of 109] male participants) with 113 observations (≥10 mm) categorized as CT/MRI LR-4 (53.1%; 60 of 113) or LR-M (46.9%; 53 of 113). CEUS resulted in management recommendation changes in 33.6% (95% CI: 25, 43; 38 of 113) of observations; among these, 95% (95% CI: 82, 99; 36 of 38) were correct. A total of 30.1% (34 of 113) of CT/MRI LR-4 and LR-M observations were categorized at CEUS as LI-RADS category LR-5 (definite HCC), making biopsy unnecessary; 94% (32 of 34) of these categorizations were correct. Of CT/MRI LR-4 observations, 7% (four of 60) were categorized as CEUS LR-M; subsequent biopsy confirmed non-HCC malignancy in all participants. Clinical impact of CEUS was more substantial for observations 20 mm or larger (n = 68); CEUS helped appropriately categorize both LR-5 and LR-M lesions as HCC and non-HCC malignancies, respectively, and resulted in management recommendation changes in 40% (27 of 68) of observations with 100% accuracy. Conclusion CEUS resolved some high-risk indeterminate liver observations (categorized as LR-4 and LR-M at CT or MRI), with particularly high clinical impact for observations measuring at least 20 mm. Clinical trial registration no. NCT03318380 © RSNA, 2025 Supplemental material is available for this article.
引用
- Lyshchik A, Kuon Yeng Escalante C, Siu Xiao T, et al. Contrast-enhanced US of High-Risk Indeterminate Focal Liver Observations Categorized as LR-4 or LR-M at CT/MRI. Radiology. 2025. PMID: 39835975. doi:10.1148/radiol.240916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。